Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00737594 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
A Phase 2 study, sponsored by Sucampo Pharma Americas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00737594: Clinical Trial Phase 2 study, sponsored by Sucampo Pharma Americas.
NCT00737594 is a Phase 2 study that was terminated before completion, run by Sucampo Pharma Americas. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00737594, a Phase 2 study, was terminated before completion, sponsored by Sucampo Pharma Americas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the efficacy and safety of cobiprostone (at two dose levels) as compared to placebo for lowering portal hypertension.
Interventions
- DRUG Placebo
- DRUG Cobiprostone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Why NCT00737594 stopped before completion
NCT00737594 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00737594 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00737594 about?
NCT00737594 is a clinical study titled "Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension". The primary purpose of this study is to determine the efficacy and safety of cobiprostone (at two dose levels) as compared to placebo for lowering portal hypertension.
What is the current status of trial NCT00737594?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2008-07. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00737594?
The interventions under investigation include: Placebo (DRUG), Cobiprostone (DRUG).
Who is sponsoring clinical trial NCT00737594?
This trial is sponsored by Sucampo Pharma Americas, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00737594's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia